News coverage about ObsEva (NASDAQ:OBSV) has been trending somewhat positive on Monday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ObsEva earned a daily sentiment score of 0.06 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.1003588105573 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
ObsEva (OBSV) opened at $9.78 on Monday. ObsEva has a one year low of $5.00 and a one year high of $14.69.
ObsEva (NASDAQ:OBSV) last issued its earnings results on Tuesday, November 14th. The company reported ($0.59) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.01). The firm’s quarterly revenue was up NaN% compared to the same quarter last year. sell-side analysts predict that ObsEva will post -2.31 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “ObsEva (OBSV) Earns Daily Media Sentiment Rating of 0.06” was published by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.com-unik.info/2018/01/08/obseva-obsv-earns-daily-media-sentiment-rating-of-0-06.html.
ObsEva Company Profile
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
What are top analysts saying about ObsEva? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ObsEva and related companies.